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Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and is
divided into two major histological subgroups, i.e., embryonal (ERMS) and alveolar RMS
(ARMS). RMS can show HEDGEHOG/SMOOTHENED (HH/SMO) signaling activity and
several clinical trials using HH inhibitors for therapy of RMS have been launched. We here
compared the antitumoral effects of the SMO inhibitors GDC-0449, LDE225, HhA, and
cyclopamine in two ERMS (RD, RUCH-2) and two ARMS (RMS-13, Rh41) cell lines. Our
data show that the antitumoral effects of these SMO inhibitors are highly divers and do not
necessarily correlate with inhibition of HH signaling. In addition, the responsiveness of the
RMS cell lines to the drugs is highly heterogeneous. Whereas some SMO inhibitors (i.e.,
LDE225 and HhA) induce strong proapoptotic and antiproliferative effects in some RMS
cell lines, others paradoxically induce cellular proliferation at certain concentrations (e.g.,
10µM GDC-0449 or 5µM cyclopamine in RUCH-2 and Rh41 cells) or can increase HH
signaling activity as judged by GLI1 expression (i.e., LDE225, HhA, and cyclopamine).
Similarly, some drugs (e.g., HhA) inhibit PI3K/AKT signaling or induce autophagy (e.g.,
LDE225) in some cell lines, whereas others cannot (e.g., GDC-0449). In addition, the
effects of SMO inhibitors are concentration-dependent (e.g., 1 and 10µM GDC-0449
decrease GLI1 expression in RD cells whereas 30µM GDC-0449 does not). Together
these data show that some SMO inhibitors can induce strong antitumoral effects in
some, but not all, RMS cell lines. Due to the highly heterogeneous response, we propose
to conduct thorough pretesting of SMO inhibitors in patient-derived short-term RMS
cultures or patient-derived xenograft mouse models before applying these drugs to RMS
patients.
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Introduction
Of the major rhabdomyosarcoma (RMS) subtypes in children, embryonal RMS (ERMS) accounts
for approximately two-third of cases. It frequently shows loss of heterozygosity of 11p15.5 and
overexpression of IGF2. The other subtype is alveolar RMS (ARMS). Seventy-five percent of ARMS
harbor reciprocal chromosomal translocations resulting in fusion genes of PAX3 or PAX7 and of
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the forkhead transcription factor, FOXO1. Twenty-five percent
of ARMS are fusion-negative as are all ERMS. ARMS has a
very poor prognosis especially when metastatic (<20% long-
term survival) (1). Although the majority of ERMS patients expe-
rience more favorable outcomes, treatment failure and toxicity
remain substantial. Furthermore, long-term survival of patients
with metastatic ERMS is still merely 40% (1). The improvement
of treatment schemes is therefore important not only in the
combat against ARMS but also against ERMS. This can be only
assured if we increase our current knowledge of the basic biology
of RMS.
We and others recently showed that predominantly ERMS and
fusion-negative ARMS are characterized by high HEDGEHOG
(HH) signaling activity (2, 3). Thus, the major marker genes of
active HH signaling GLI1 and PATCHED1 (PTCH) are expressed
at significantly higher levels in both subgroups compared to
fusion-positive ARMS that however also show activation of the
pathway. These results implicate that RMS might be sensitive
toward a targeted therapy using smallmolecule inhibitors directed
against components of the HH signaling pathway.
The HH signaling pathway plays a critical role in development,
cell fate decisions, and tissue growth. Components of the canoni-
cal HH signaling cascade are the HH ligand, the transmembrane
protein PTCH that acts as a receptor for HH proteins, the seven-
pass transmembrane protein and signaling partner of PTCH,
SMOOTHENED (SMO), and the family of GLI transcription fac-
tors. In the absence of HH, PTCH inhibits SMO. Binding of HH to
PTCH suspends this inhibition. Through a series of poorly under-
stood events that involves SMO-trafficking to the primary cilia,
SMO activates the transcription factors GLI2 and GLI3 and the
expression of downstream target genes [reviewed in Ref. (4)]. The
HH signal also induces the expression of GLI1, which thus ampli-
fies the HH signal. Another downstream target of the pathway
is PTCH, which in contrast regulates HH signaling in a negative
feedback loop. Together GLI1 and PTCH mRNAs are considered
as reliablemarkers for the pathway’s activity [reviewed in Ref. (5)].
Finally, also IGF2 expression can be regulated by HH signaling (6,
7). Gene expression data revealed that IGF2 is frequently overex-
pressed in ERMS and ARMS and plays also a key role in the for-
mation, proliferation, growth, andmetastasis of RMS [reviewed in
Ref. (8)].
Several drugs targeting the HH pathway exist that already have
entered clinical phase I/II trials. The first inhibitor of the HH
pathway discovered was cyclopamine. Cyclopamine is a natural
product that can be isolated from corn lilies and that binds and
inhibits SMO (9). However, because of its limited potency and
poor oral solubility, it is not suitable for clinical development
(10). Recently, more potent derivatives of cyclopamine and small
molecule antagonists targeting SMO have been identified. One of
them, i.e., GDC-0449 (vismodegib) has already been approved for
advanced basal cell carcinoma (11) and is also used in clinical
trials for adult RMS patients. Another compound is LDE225
(sonidegib), which is well-tolerated by the patients and which is
currently evaluated in phase II clinical trials for medulloblastoma
and RMS. LDE225 also just met primary endpoint in a trial for
patients with advanced basal cell carcinoma. In addition, several
other compounds, such as BMS-833923 or PF04449913, are being
investigated in a range of advanced cancers (10). Table S1 in
Supplementary Material is providing a short overview of the four
SMO inhibitors used in this study.
SMOOTHENED inhibitors can vary in their capacity to block
canonical HH signaling as estimated by GLI1 expression. They
also can have variable potency in blocking the activity of SMO
mutational activating variants. Examples are GDC-0449 and
HhAntag (HhA). Whereas GDC-0449 has a robust potency
against the SMO-E518K variant, but is weakly active against
SMOD473H,HhA is essentially equipotent against all SMO alleles
(12). Interestingly, besides inhibiting canonical HH signaling,
several SMO inhibitors including cyclopamine and GDC-0449
activate a non-canonical SMO/Ca2+/AMPK-dependent signaling
cascade that may induce a Warburg-like effect, whereas other
SMO modulators such as LDE225 do not (13). Together, these
data show that SMO inhibitors differ substantially in their mode
of action.
Here, we compared the effects of GDC-0449, LDE225, HhA,
and cyclopamine with respect to HH pathway inhibition and
their potential to inhibit proliferation, to induce apoptosis and to
modulate the differentiation status of four different RMS cell lines.
We also compared their impact on the activity of other signaling
molecules including AKT and AMPK. Our data reveal that the
compounds differ extraordinarily in modulation of the above-
mentioned parameters and that the responsiveness of the RMS cell
lines is highly heterogeneous.
Materials and Methods
Reagents
HhA was from Genentech (San Francisco, CA, USA), GDC-0449
(Vismodegib) from Selleckchem (Munich, Germany) and LDE225
(NVP-LDE225) from Active Biochem (Bonn, Germany). For
in vitro assays, the drugs were dissolved in DMSO. Cyclopamine
was purchased from Sigma-Aldrich (St. Louis, MO, USA) and
was dissolved in Ethanol. All compounds were easy to solubilize
in the respective solvents. For proliferation assays, Annexin V/PI
staining andWestern blot the final DMSO/ethanol concentrations
were uniform in all samples, i.e., the medium contained 0.03%
(v/v) DMSO and 0.1% (v/v) ethanol, whereas for gene expression
analysis and WST-1 assay the solvent was DMSO for GDC-0449,
LDE225, and HhA and ethanol for cyclopamine. The final drug
concentrations used for in vitro analysis are indicated in the
respective experiments.
Cell Culture
The human ERMS cell lines RD and RUCH-2 and the ARMS
cell lines RMS-13 (also known as Rh30) and Rh41 (also called
Rh4) were obtained from ATCC [for cell lines see Ref. (14)].
The ERMS and ARMS cell lines were cultured in DMEM and
in RPMI, respectively, 10% FCS (20% FCS for Rh41), and 1%
penicillin/streptomycin.
For determination of apoptosis, 105 cells/well (ERMS) or
15 104 cells/well (ARMS) were seeded in six-well-plates. After
treatment for 48 h with medium supplemented with drugs or
Frontiers in Oncology | www.frontiersin.org June 2015 | Volume 5 | Article 1302
Ridzewski et al. Hedgehog inhibitors and rhabdomyosarcoma
solvent as indicated in the respective experiments, apoptosis
was determined by flow cytometry on a FACSCalibur (BD
Biosciences, Heidelberg, Germany) after staining of the cells
with Annexin V-FITC (BD Biosciences, Heidelberg, Germany)
and Propidium Iodide (PI, Miltenyi Biotec, Bergisch Gladbach,
Germany).
For BrdU incorporation and WST assay, 4000 cells/well were
seeded in 96-well-plates. For the BrdU assay, cells were incu-
bated for 24 h with the respective drugs in the presence of BrdU.
BrdU incorporationwasmeasured using a Cell Proliferation BrdU
ELISA (Roche Diagnostics GmbH, Mannheim, Germany). The
data are presented as the percentage of the incorporation mea-
sured in time-matched solvent-treated controls taken as 100%.
For WST-1 assay, cells were incubated for 24 h with the respective
drugs. Four hours before the end of incubation, WST-1 reagent
(Roche Diagnostics, Mannheim, Germany) was added as recom-
mended by the manufacturer. The amount of produced formazan
dye (quantitated by spectrophotometer at a wavelength of 450 nm)
correlates to metabolic active cells.
Data shown summarize three independent experiments per-
formed as duplicates (apoptosis assay) or triplicates (BrdU incor-
poration assay) or two independent experiments performed as
triplicates (WST-1 assay).
Real-Time Quantitative RT–PCR-Analyses
For gene expression analysis, 105 cells/well (ERMS) or 15 104
cells/well (ARMS) were seeded in six-well-plates. After incuba-
tion of the cells for 24 h, total RNA was isolated using TRIzol
Reagent (Invitrogen GmbH, Karlsruhe, Germany) and cDNAwas
synthesized using Superscript II and random hexamers (Invitro-
gen, Karlsruhe, Germany). Quantitative RT–PCR of target cDNAs
was performed using SYBR-green based assays on an ABI Prism
HT 7900 Detection System instrument and software (Applied
Biosystems, Darmstadt, Germany). The primers for amplification
of target transcripts are shown in the Table S2 in Supplementary
Material. All primers used in study were intron-flanking, except
of the primers for 18S and hMYOD. Expression levels of 18S
rRNA served to normalize the transcript levels. Each sample was
measured in triplicates. Expression of major components of the
HH signaling pathway was analyzed once. All other data shown
are the summary of two independent experiments performed in
duplicates. Graphs represent the mean value of all measurements
plus SEM.
Western Blot Analysis
Preparation of cell lysates and determination of protein concentra-
tions were done as described previously (15). Primary antibodies
used to detect the individual target proteins and corresponding
secondary antibodies are shown in Table S3 in Supplementary
Material. All Western blots shown are representative for at least
two independent experiments.
Statistical Analysis
When comparing two samples, statistical differences were ana-
lyzed using Student’s t-test. Data were considered significant when
p< 0.05.
Results
Effects of GDC-0449, LDE225, HhA, and
Cyclopamine on HH Signaling Activity and on the
Expression of IGF2 and of Muscle Differentiation
Markers
We first examined whether the two ERMS cell lines, RD and
RUCH-2, and the two ARMS cell lines, RMS-13 and Rh41, used
in the study express the major components of the HH signaling
cascade SHH, SMO, PTCH, and GLI1-3. Of these genes, GLI1 and
PTCH are regulated by the HH signal and thus are HH pathway
target genes. As shown in Figure S1 in Supplementary Material,
SHH, SMO, and PTCH and the transcriptional effectors GLI1,
GLI2, and GLI3 were expressed in all cell lines. Expression of
GLI1, GLI3, PTCH, and SMO was highest in RMS-13 cells that
show an amplification of GLI1 (16). Furthermore, we detected
SHH expression that was highest in RUCH-2 cells. In summary, all
RMS cell lines express the major components of the HH signaling
pathway. This is similar to data previously published by Graab
et al. (17).
BecauseGLI1 and PTCH expression were suggestive for canon-
ical HH signaling activity (i.e., via the HH/PTCH/SMO/GLI axis)
in the different cell lines, we examined whether it is possible
to inhibit HH signaling using the SMO inhibitors GDC-0449,
LDE225, HhA, and cyclopamine. For this purpose, we first deter-
mined the optimal conditions under which each inhibitor may
block HH signaling. In order to measure HH signaling activity,
the transcription of the HH pathway indicator GLI1 was analyzed
by qRT-PCR.
In the cell line RD, significant inhibition of GLI1 expression
was revealed for 1, 10, and 50µM GDC-0449 and LDE225,
and for 1–50µM HhA (Figure 1). Interestingly, we found that
30µM of GDC-0449 or LDE225 did not further decrease HH
signaling activity but restored the activity to basal level or above
(Figure 1). Similarly, cyclopamine increased GLI1 expression and
the increase was significant at 1µM (Figure 1).
In RUCH-2 cells, the dose-response analyses revealed that
GDC-0449 did not significantly modulate GLI1 expression at any
concentration, whereas LDE225 and HhA inhibited GLI1 expres-
sion at 30 and 50µM, and 10 and 50µM, respectively. In addition,
and similar to RD cells, cyclopamine increasedGLI1 expression at
concentrations of 0.1, 1, and 5µM (Figure 1).
In RMS-13 cells, which show GLI1 amplification, the drugs
did not decrease GLI1 expression levels at any concentrations
used in the experiments. Rather GLI1 expression was increased,
which was particularly obvious for LDE225 and cyclopamine
(Figure 1).
In Rh41, we found that GDC-0449 moderately inhibited GLI1
expression at any concentration whereas LDE225 inhibited GLI1
expression only at 10 and 30µM, and increased it at 50µM.
HhA inhibited GLI1 expression at a concentration of 0.1 and
1µM, whereas higher concentrations also resulted in restoration
or increase inGLI1 expression. Cyclopamine never inhibitedGLI1
expression but induced it for 1–10µM (Figure 1).
Together, these data show that ERMS andARMS cell lines show
tumor-intrinsic HH signaling activity as estimated by modula-
tion of GLI1 expression after treatment with SMO – antagonists.
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FIGURE 1 | Relative quantification of GLI1 expression in RD, RUCH-2,
RMS-13, and Rh41 after treatment with GDC-0449, LDE225, HhA, and
cyclopamine (cp) at the concentration indicated. Gene expression
levels were normalized to 18S rRNA expression levels. The respective
solvent-controls (solv) for each experiment were set to 1. All data represent
at least two independent experiments performed in duplicates and
measured in triplicates. The data are represented as meanSEM;
*p<0.05; **p<0.01; ***p<0.001.
Furthermore, our data demonstrate that SMO inhibitors – depen-
dent on the concentration – may paradoxically activate GLI1
transcription in some RMS cell lines.
We next measured the expression of IGF2 that plays an impor-
tant role in RMS pathology (8) and is regulated by HH signaling
in specific cellular settings (6, 7). Whereas RUCH-2 cells did not
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express IGF2, the levels of IGF2 were regulated by all drugs in the
remaining three cell lines, however to a variable extent (Figure S2
in Supplementary Material). In RD cells, IGF2 transcription was
inhibited by 0.1, 30, and 50µM GDC-0449, by 50µM LDE225
and by 10, 30, and 50µM HhA. Cyclopamine had no effect and
0.1µM HhA increased the IGF2 levels. In RMS-13, IGF2 expres-
sion was significantly inhibited upon treatment with 50µMHhA
or LDE225 and with 0.1 and 1µM GDC-0449. By contrast, 0.1
and 1µM HhA as well as 1–10µM cyclopamine resulted in a
significant up-regulation of the expression of this gene. This was
different in Rh41 cells. In this cell line, the IGF2mRNA level was
significantly decreased only with 10µM cyclopamine, whereas all
other drugs rather increased it. This was specifically obvious after
GDC-0449-treatment (Figure S2 in Supplementary Material).
Finally, we also examined the expression of the early and late
muscle differentiation markers MYOD and MYH1, respectively
(Figure S3 and S4 in Supplementary Material).
RUCH-2 cells neither expressedMYOD norMYH1.
In RD cells, MYOD transcription was inhibited by 0.1 and
50µM GDC-0449, whereas 1µM GDC-0449 induced it. MYOD
expressionwas also inhibited by 0.1, 10, and 50µMLDE225, by 10,
30, and 50µM HhA and 0.1 and 1µM cyclopamine. In RMS-13,
MYOD expressionwas significantly inhibited upon treatmentwith
1 and 30µMGDC-0449, 30 and 50µMLDE225 or HhA and with
0.1 and 1µMcyclopamine. In Rh41 cells, GDC-0449 and LDE225
inducedMYOD expression at any concentration.MYOD was also
induced by 10–50µMHhA, whereas cyclopamine had no effect.
MYH1 transcription in RD cells was inhibited by 30 and 50µM
GDC-0449, by 10–50µM LDE225, by 1–50µM HhA, whereas
it was induced by cyclopamine at any concentration. In RMS-
13, MYH1 expression was induced by GDC-0449 (significant
for 0.1 and 30µM) and by LDE225 (significant for 1–30µM).
HhA induced the expression at a concentration of 0.1 and 1µM,
whereas 30 and 50µM inhibited it. Inhibition of MYH1 expres-
sion was also seen with 5µM cyclopamine. In Rh41, MYH1
expression was induced by GDC-0449 (significant for 0.1, 10, and
30µM) and by 1 and 30µM LDE225, whereas 50µM inhibited it.
HhA induced the expression at a concentration of 0.1 and 1µM,
whereas 30 and 50µMinhibited it. Inhibition ofMYH1 expression
was also seen with 1–10µM cyclopamine.
Together, SMO inhibitors may – dependent on the concen-
tration – activate or inhibit transcription of IGF2 and that of
muscle differentiation markers in some RMS cell lines. Further-
more, the responses of the cell lines are highly variable and differ
enormously from each other.
Effects of GDC-0449, LDE225, HhA, and
Cyclopamine on Cellular Proliferation and
Apoptosis
Next, we assessed the antiproliferative and proapoptotic effects
of SMO inhibitors. For this purpose, we used concentrations
that either have decreased or did not impact (10 and 30µM,
respectively) on GLI1 expression in most experimental settings.
Cyclopamine was used only at a concentration of 5µM.
As shown by BrdU assays, the antiproliferative effects of SMO
inhibitors dramatically varied between the cell lines: in RD
cells, 30µM LDE225 and 10µM and 30µM HhA reduced the
proliferation rate of RD cells approximately by 55% and 30 and
50%, respectively (Figure 2). Thirty micromoles of GDC-0449,
10µM LDE225 and cyclopamine did not show any antiprolifera-
tive effects, whereas 10µMGDC-0449 significantly increased the
proliferation rate (Figure 2). This was similar in RUCH-2 cells,
in which the proliferation was significantly reduced by 30µM
LDE225 and by 10 and 30µM HhA (Figure 2). Ten micromoles
of LDE225 and 30µM GDC-0449 had no effects, whereas 10µM
GDC-0449 and 5µM cyclopamine significantly increased it (by
approximately 50 and 100%, respectively) (Figure 2). In RMS-13,
proliferation was reduced by 30µMGDC-0449, by 10 and 30µM
LDE225 and by 30µM HhA (Figure 2). In Rh41, none of the
drugs inhibited proliferation (Figure 2). However, proliferation-
inducing effects were seen for 10 and 30µMGDC-0449, for 10µM
LDE225 and for cyclopamine (Figure 2; for RD and Rh41 the
results were confirmed by simple cell counting; see Figure S5 in
Supplementary Material).
As far as apoptosis is concerned, 30µM LDE225 significantly
increased the apoptosis rate (as estimated by increase of Annexin
V positive cells) of RD cells as did 30µM HhA (Figure 3).
Ten micromoles of LDE225 or HhA as well as GDC-0449 and
cyclopamine did not trigger apoptosis (Figure 3). The substances
had similar effects in RMS-13 and Rh41 cells (Figure 3). Assess-
ment of apoptosis in RUCH-2 cells was not possible due to
unstable results obtained from three measurements.
Together, these data demonstrate that the responsiveness of the
cell lines to four distinct SMO inhibitors is very heterogeneous. In
general, the results show that cyclopamine at the used concentra-
tion neither induces apoptosis nor reduces proliferation of any of
the cell lines. It rather seems to increase the proliferation rate in
RUCH-2 and Rh41 cells. In addition, GDC-0449 is less effective
compared to LDE225 or HhA that have the capacity to induce
apoptosis and antiproliferative effects dependent on the cell line
and the applied drug concentration.
Effects of GDC-0449, LDE225, HhA, and
Cyclopamine on PI3K/AKT/mTOR Signaling
Activity and Activation of AMPK and LC3
HEDGEHOG signaling can influence the activation status of
PI3K/AKT signaling (18, 19, 20) and can inhibit autophagy
(21). In addition, HH inhibitors can impact on a non-canonical
SMO/Ca2+/AMPK-dependent signaling cascade (13). Therefore,
we examined the phosphorylation status of AKT and AMPK. We
also measured the phosphorylation status of S6 that can be taken
as surrogate readout for mTOR activity, and the activation status
of caspase 3. Autophagy was assessed by the expression levels of
the cytosolic 16 kDa large LC3-I and the 14 kDa large LC3-II, the
latter being the lipidated form of LC3-I and specifically associates
with autophagosomemembranes and thus reflect autophagosome
numbers (22). In the following, the most important and clear-cut
findings from at least two independent Western blot analyses are
summarized.
In RD cells, GDC-0449, LDE225, and cyclopamine did not
influence the phosphorylation status of AKT or S6 in comparison
to the solvent (Figure 4). In contrast, treatment withHhA reduced
AKT/pAKT levels in RD cells (Figure 4). An induction of AMPK
phosphorylation was seen with 30µM GDC-0449 and with 10
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FIGURE 2 | BrdU incorporation in RD, RUCH-2, RMS-13, and Rh41
cells after incubation with GDC-0449, LDE225, HhA, and
cyclopamine (cp) at the concentration indicated. BrdU-incorporation
is shown as percentage of respective solvent-controls (solv) that were set
to 100%. The data are represented as meanSEM; *p<0.05; **p<0.01;
***p<0.001.
and 30µM LDE225 (Figure 4). Caspase 3 activity was induced
by 30µM LDE225 as was autophagy (Figure 4). Increased LC3-II
levels were also seen after treatment with HhA and cyclopamine
at any concentration (Figure 4).
In RUCH-2 cells and similar to RD cells, HhA reduced
AKT/pAKT levels and 30µM LDE225 induced caspase 3 activ-
ity and autophagy (Figure 4). Furthermore, 30µM LDE225
reduced pAMPK phosphorylation (Figure 4). An increase in
LC3-II expression was also detected with HhA and cyclopamine
(Figure 4).
In RMS-13 cells, we found a clear-cut effect of 30µM LDE225
on caspase 3 activation and on LC3-II levels (Figure 4). LC3-
II was also increased by 30µM HhA and by cyclopamine at any
concentration (Figure 4).
In Rh41 cells, GDC-0449 and HhA did not exert any obvious
effect (Figure 4). LDE225 at a concentration of 30µM strongly
induced caspase 3 activity and increased LC3-II levels (Figure 4).
Increase in LC3-II was also detected after treatment of the cells
with cyclopamine (Figure 4).
In summary, these data show that the drugs exert highly het-
erogeneous effects on the cell lines and that the responsiveness of
the cell lines is very heterogeneous as well.
Discussion
The HH pathway controls cell proliferation, differentiation, and
tissue patterning. Thus, it is not surprising that a pathological
activation of the pathway results in tumor formation. The cancers
include those of the skin, brain, prostate, lungs, breast, and also
subgroups of RMS. Therefore, the HH pathway is considered
a good target for therapy. Several compounds exist and their
efficacies are currently tested in clinical studies.One of these drugs
is GDC-0449 that has already been approved for advanced and
metastasizing basal cell carcinoma (10).
Despite these promising trends, HH inhibitors can rapidly lead
to resistance. For example, GDC-0449 resistance has occurred
in medulloblastoma through a D473H mutation in SMO, which
prevented GDC-0449-SMO binding while maintaining aberrant
HH signaling (23, 24). It also has been reported that resistance
under LDE225 treatment include amplification of GLI2, aberrant
up-regulation of PI3K signaling, and SMO mutations (25). This
indicates that it is important to select those inhibitors for therapy
that instantly and very potently inhibit proliferation and/or induce
apoptosis of the tumor cells to circumvent the occurrence of these
resistance mechanisms.
Our data on RMS show that LDE225 and HhA meet these
criteria in RUCH-2, RD, and RMS-13 cell lines at concentrations
between 10 and 30µM, whereas cyclopamine and also GDC-0449
do not. Instead the latter drugs rather increased BrdU incorpo-
ration and exerted no proapoptotic effects. The increase in BrdU
incorporation upon cyclopamine and GDC-0449 treatment are
hard to explain, especially because it was neither correlated with
induction of HH signaling nor IGF2 overexpression. Vice versa,
the antiproliferative and proapoptotic effects of LDE225 and HhA
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FIGURE 3 | Analysis of Annexin V/PI positivity of RD, RMS-13 and Rh41 cells after treatment with GDC-0449, LDE225, HhA, and cyclopamine (cp) at
the concentration indicated.
(Continued)
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FIGURE 3 | Continued
Apoptosis was analyzed by FACS after staining of the cells with Annexin V
and Propidium Iodide (PI). Vital cells are Annexin V /PI , early-apoptotic
(Annexin V+/PI ) and late-apoptotic cells (Annexin V+/PI+) were
summarized as Annexin V+ cells and Annexin V /PI+ are necrotic cells,
respectively. All data represent at least three independent experiments
measured in duplicates. The data are represented as meanSEM; solv,
solvent.
FIGURE 4 |Western blot analysis of RD, RUCH-2, RMS-13, and Rh41 after treatment with GDC-0449, LDE225, HhA, and cyclopamine (cp) at the
concentration indicated. solv, solvent.
not necessarily correlated with inhibition of HH signaling. By
contrast, we observed that these compounds (and also the other
used in the study) had the potency to increase GLI1 expression
levels. This was dependent on the cell line, on the applied drug,
and the respective drug concentration. For example, treatment of
RMS-13 cells with 30µM HhA or LDE225 resulted in a strong
antiproliferative and proapoptotic effect but in an up-regulation
of GLI1. Curiously, the proapoptotic effects (as measured by
Annexin V labeling) were associated with caspase 3 activity in
LDE225-treated cells, but not inHhA-treated ones, indicating that
HhA may trigger caspase 3-independent apoptosis.
We are not aware of any study showing that SMO inhibitors
can induce GLI1 expression. Although it is possible that this effect
is specific for RMS cell lines, it is more likely that the inhibitors
influence other signaling molecules that in turn activate GLI1
expression in a dose-dependent manner. This scenario has been
demonstrated for the SMO agonist SAG (26). Thus, Chen and
colleagues showed that SAG induced HH signaling activity with
an EC50 of 3 nM, but inhibited the activity at concentrations
above 1µM. The authors propose a model, in which SAG may
interact not only with SMO, but also with another cellular effec-
tor of SMO activation. According to their model, optimal SAG
concentrations induce HH pathway activation by facilitating the
association of SMO with the respective protein, whereas higher
SAG concentrations begin to inhibit this process, as the ago-
nist would independently bind both SMO and the effector (26).
Similar models may apply to SMO inhibitors.
It is also possible that the observed concentration-dependent
effects of the drugs on GLI1 expression are off-target effects
of the SMO inhibitors. Toxic effects can be rather excluded. A
good example are RD cells that show a triphasic GLI1 expression
profile, i.e., a decrease at 10µM, an increase at 30µM, and a
decrease at 50µM upon GDC-0449, LDE225, or HhA treatment,
but no triphasic changes in metabolic activity that continuously
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decreases with increasing drug concentration (compare Figure 1
and Figure S6 in Supplementary Material). Thus, an increase of
GLI1 expression (at 30µM) is not correlated with increased cell
viability (Figure S6 in Supplementary Material).
Furthermore, Dijkgraaf and colleagues (12) discussed a two-
step mechanism for SMO activation that not only requires the
transport to the cilia, but also an unidentified second activation
step that allows SMO to trigger downstream HH signaling. The
authors suggest that SMO antagonists can be subdivided in two
classes. Whereas one class of inhibitors influences trafficking of
SMO to cilia, the other class affects the activation step. They also
discuss the possibility that SMO antagonists can induce slightly
different SMO conformations that favor a particular subcellular
localization over another (12). This also could explain some of the
different effects of the inhibitors used in our study.
HEDGEHOG signaling also regulates the expression of muscle
differentiation markers. MYOD expression has been shown to
be inhibited by GLIs (27). In addition, HH signaling can inhibit
terminal muscle differentiation (28). We therefore hypothesized
that inhibition of HH signaling using SMO antagonists should
result in up-regulation of MYOD and MYH1 and thus in a more
differentiated RMS phenotype. However, our data show that this
only applied to some inhibitors at specific concentrations in spe-
cific cells lines (e.g., GDC-0449 at any concentration in Rh41
cells), whereas the genes were rather down-regulated in other cell
lines (e.g., by LDE225 in RD cells). This again indicates that the
drugs have heterogeneous effects.
It also has been demonstrated that SMO inhibitors (besides
inhibiting the canonical SMO-GLI axis) can activate a non-
canonical SMO/Ca2+/AMPK axis that triggers a rapid Warburg-
like catabolic reprograming. Induction of a Warburg-like effect
has been shown for cyclopamine and GDC-0449, but not for
LDE225, in mature 3T3-L1 adipocytes and the myoblast cell line
C2C12 (13). It has been suggested that the physiological effects
of these non-canonical endpoints, i.e., Ca2+ influx and AMPK-
mediated catabolism, are consistent with the two major reported
side effects of SMO inhibitors such asmuscle cramping andweight
loss. Although we did not measure Ca2+ influx our data shows
that the AMPK phosphorylation was indeed induced in RD cells
with 30µM GDC-0449 and with 10 and 30µM LDE225. This
indicates that also LDE225 can induce Warburg-like effect, which
apparently depends on the drug concentration and the cellular
context.
Recently, it has been demonstrated that HH signaling can
activate PI3K/AKT signaling and that, vice versa, AKT can sta-
bilize and thus activate GLI transcription factors (18, 19, 20).
In addition, mTOR, which is a downstream target of PI3K/AKT
signaling can also trigger GLI activation (29). Therefore, we ana-
lyzed whether SMO inhibitors modulate activation of AKT or
mTOR in RMS cell lines. Indeed, HhA, but none of the other
SMOantagonists, blocked phosphorylation of AKT in both ERMS
cell lines. Effects on S6 phosphorylation were not seen. Although
this suggests that there is a crosstalk between HH and AKT
signaling in at least some RMS, it is possible that HhA induces
HH-independent processes that trigger AKT inhibition.
Because HH signaling can inhibit autophagosome synthesis,
both in basal and in autophagy-induced conditions (21), we
finally investigated whether the applied drugs induced autophagy.
Indeed, our data show that HhA, LDE225, and cyclopamine can
strongly increase the levels of LC3-II. Induction of autophagy by
SMO inhibitors has also been shown in a variety of other cancer
cell lines. Examples are hepatocellular and pancreatic carcinoma,
in which the GLI inhibitor GANT61 induced autophagy that was
accompanied with reduced cell viability and increased apoptosis
both in vivo and in vitro (30, 31). The authors proposed that HH
signaling by regulating autophagy plays an important role in deter-
mining the cellular response toHH-targeted therapy in pancreatic
cancer. However, our data shows that induction of autophagy by
HH inhibitors is not necessarily accompanied by antiproliferative
or proapoptotic effects. For example, this is demonstrated in Rh41
cells that upon cyclopamine treatment showed increased LC3-II
levels, but also increased BrdU incorporation and no alteration in
the number of Annexin V positive cells.
Together, our study reveals that the mode of action of the
applied HH inhibitors differs substantially from each other.
Although HhA and LDE225 are probably the most universal HH
inhibitors and exert antitumoral effects in almost all RMS cell lines
used in our study, we propose to conduct thorough pretesting of
HH inhibitors before applying these drugs to RMS patients. This
could be done either in patient-derived short-term RMS cultures
or in patient-derived xenograft mouse models.
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